Here in the U.S., many startups are facing hard questions about how they’ve grown: bloated valuations, misaligned incentives, shallow product pipelines. The contrast with Korea’s quiet biotech ascent ...

Hillstar Bio, a leading biotechnology company focused on developing immunology therapies for autoimmune diseases, appointed ...